1
|
Sata Y, Burke SL, Eikelis N, Watson AMD, Gueguen C, Jackson KL, Lambert GW, Lim K, Denton KM, Schlaich MP, Head GA. Renal Deafferentation Prevents Progression of Hypertension and Changes to Sympathetic Reflexes in a Rabbit Model of Chronic Kidney Disease. Hypertension 2021; 78:1310-1321. [PMID: 34538104 DOI: 10.1161/hypertensionaha.121.17037] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Yusuke Sata
- Neuropharmacology Laboratory (Y.S., S.L.B., A.M.D.W., C.G., K.L.J., K.L., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Human Neurotransmitters Laboratory (Y.S., M.P.S., G.W.L., N.E.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Faculty of Medicine, Nursing and Health Sciences, Central Clinical School (Y.S.), Monash University, Melbourne, VIC, Australia.,Department of Cardiology, Alfred Hospital, Melbourne, VIC, Australia (Y.S.)
| | - Sandra L Burke
- Neuropharmacology Laboratory (Y.S., S.L.B., A.M.D.W., C.G., K.L.J., K.L., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Nina Eikelis
- Human Neurotransmitters Laboratory (Y.S., M.P.S., G.W.L., N.E.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Iverson Health Innovation Research Institute and School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia (N.E., G.W.L.)
| | - Anna M D Watson
- Neuropharmacology Laboratory (Y.S., S.L.B., A.M.D.W., C.G., K.L.J., K.L., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Department of Diabetes, Central Clinical School (A.M.D.W.), Monash University, Melbourne, VIC, Australia
| | - Cindy Gueguen
- Neuropharmacology Laboratory (Y.S., S.L.B., A.M.D.W., C.G., K.L.J., K.L., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Kristy L Jackson
- Neuropharmacology Laboratory (Y.S., S.L.B., A.M.D.W., C.G., K.L.J., K.L., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences (K.L.J), Monash University, Melbourne, VIC, Australia
| | - Gavin W Lambert
- Human Neurotransmitters Laboratory (Y.S., M.P.S., G.W.L., N.E.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Iverson Health Innovation Research Institute and School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia (N.E., G.W.L.)
| | - Kyungjoon Lim
- Neuropharmacology Laboratory (Y.S., S.L.B., A.M.D.W., C.G., K.L.J., K.L., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Department of Physiology, Anatomy and Microbiology, La Trobe University, Melbourne, VIC, Australia (K.L.)
| | - Kate M Denton
- Cardiovascular Program, Monash Biomedicine Discovery Institute and Department of Physiology, Monash University, Clayton, VIC, Australia (K.M.D.)
| | - Markus P Schlaich
- Human Neurotransmitters Laboratory (Y.S., M.P.S., G.W.L., N.E.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Departments of Cardiology and Nephrology, Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit, University of Western Australia, Royal Perth Hospital (M.P.S.)
| | - Geoffrey A Head
- Neuropharmacology Laboratory (Y.S., S.L.B., A.M.D.W., C.G., K.L.J., K.L., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.,Department of Pharmacology (G.A.H.), Monash University, Melbourne, VIC, Australia
| |
Collapse
|
2
|
Sata Y, Burke SL, Gueguen C, Lim K, Watson AM, Jha JC, Eikelis N, Jackson KL, Lambert GW, Denton KM, Schlaich MP, Head GA. Contribution of the Renal Nerves to Hypertension in a Rabbit Model of Chronic Kidney Disease. Hypertension 2020; 76:1470-1479. [DOI: 10.1161/hypertensionaha.120.15769] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Overactivity of the sympathetic nervous system and high blood pressure are implicated in the development and progression of chronic kidney disease (CKD) and independently predict cardiovascular events in end-stage renal disease. To assess the role of renal nerves, we determined whether renal denervation (RDN) altered the hypertension and sympathoexcitation associated with a rabbit model of CKD. The model involves glomerular layer lesioning and uninephrectomy, resulting in renal function reduced by one-third and diuresis. After 3-week CKD, blood pressure was 13±2 mm Hg higher than at baseline (P<0.001), and compared with sham control rabbits, renal sympathetic nerve activity was 1.2±0.5 normalized units greater (P=0.01). The depressor response to ganglion blockade was also +8.0±3 mm Hg greater, but total norepinephrine spillover was 8.7±3.7 ng/min lower (bothP<0.05). RDN CKD rabbits only increased blood pressure by 8.0±1.5 mm Hg. Renal sympathetic activity, the response to ganglion blockade and diuresis were similar to sham denervated rabbits (non-CKD). CKD rabbits had intact renal sympathetic baroreflex gain and range, as well as normal sympathetic responses to airjet stress. However, hypoxia-induced sympathoexcitation was reduced by −9±0.4 normalized units. RDN did not alter the sympathetic response to hypoxia or airjet stress. CKD increased oxidative stress markers Nox5 and MCP-1 (monocyte chemoattractant protein-1) in the kidney, but RDN had no effect on these measures. Thus, RDN is an effective treatment for hypertension in this model of CKD without further impairing renal function or altering the normal sympathetic reflex responses to various environmental stimuli.
Collapse
Affiliation(s)
- Yusuke Sata
- From the Neuropharmacology Laboratory (Y.S., S.L.B., C.G., K.L., K.L.J., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Human Neurotransmitters Laboratory (Y.S., M.P.S.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Faculty of Medicine, Nursing and Health Sciences, Central Clinical School (Y.S.), Monash University, Melbourne, VIC, Australia
- Department of Cardiology, Alfred Hospital, Melbourne, VIC, Australia (Y.S.)
| | - Sandra L. Burke
- From the Neuropharmacology Laboratory (Y.S., S.L.B., C.G., K.L., K.L.J., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Cindy Gueguen
- From the Neuropharmacology Laboratory (Y.S., S.L.B., C.G., K.L., K.L.J., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Kyungjoon Lim
- From the Neuropharmacology Laboratory (Y.S., S.L.B., C.G., K.L., K.L.J., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Department of Physiology, Anatomy and Microbiology, La Trobe University, Melbourne, VIC, Australia (K.L.)
| | - Anna M.D. Watson
- Department of Diabetes, Central Clinical School (A.M.D.W., J.C.J.), Monash University, Melbourne, VIC, Australia
| | - Jay C. Jha
- Department of Diabetes, Central Clinical School (A.M.D.W., J.C.J.), Monash University, Melbourne, VIC, Australia
| | - Nina Eikelis
- Iverson Health Innovation Research Institute and School of Health Science, Swinburne University of Technology, Hawthorn, VIC, Australia (N.E., G.W.L.)
| | - Kristy L. Jackson
- From the Neuropharmacology Laboratory (Y.S., S.L.B., C.G., K.L., K.L.J., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
| | - Gavin W. Lambert
- Iverson Health Innovation Research Institute and School of Health Science, Swinburne University of Technology, Hawthorn, VIC, Australia (N.E., G.W.L.)
| | - Kate M. Denton
- Cardiovascular Program, Monash Biomedicine Discovery Institute and Department of Physiology, Monash University, Clayton, VIC, Australia (K.M.D.)
| | - Markus P. Schlaich
- Human Neurotransmitters Laboratory (Y.S., M.P.S.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit, University of Western Australia (M.P.S.)
- Departments of Cardiology (M.P.S.), Royal Perth Hospital, Western Australia, Australia
- Nephrology (M.P.S.), Royal Perth Hospital, Western Australia, Australia
| | - Geoffrey A. Head
- From the Neuropharmacology Laboratory (Y.S., S.L.B., C.G., K.L., K.L.J., G.A.H.), Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
- Department of Pharmacology (G.A.H.), Monash University, Melbourne, VIC, Australia
| |
Collapse
|
3
|
Differential sympathetic response to lesion-induced chronic kidney disease in rabbits. Kidney Int 2020; 98:906-917. [DOI: 10.1016/j.kint.2020.03.039] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 03/17/2020] [Accepted: 03/26/2020] [Indexed: 01/29/2023]
|
4
|
Cobos-Puc L, Aguayo-Morales H. Cardiovascular Effects Mediated by Imidazoline Drugs: An Update. Cardiovasc Hematol Disord Drug Targets 2019; 19:95-108. [PMID: 29962350 DOI: 10.2174/1871529x18666180629170336] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 05/05/2017] [Accepted: 04/18/2018] [Indexed: 06/08/2023]
Abstract
OBJECTIVE Clonidine is a centrally acting antihypertensive drug. Hypotensive effect of clonidine is mediated mainly by central α2-adrenoceptors and/or imidazoline receptors located in a complex network of the brainstem. Unfortunately, clonidine produces side effects such as sedation, mouth dry, and depression. Moxonidine and rilmenidine, compounds of the second generation of imidazoline drugs, with fewer side effects, display a higher affinity for the imidazoline receptors compared with α2-adrenoceptors. The antihypertensive action of these drugs is due to inhibition of the sympathetic outflow primarily through central I1-imidazoline receptors in the RVLM, although others anatomical sites and mechanisms/receptors are involved. Agmatine is regarded as the endogenous ligand for imidazoline receptors. This amine modulates the cardiovascular function. Indeed, when administered in the RVLM mimics the hypotension of clonidine. RESULTS Recent findings have shown that imidazoline drugs also exert biological response directly on the cardiovascular tissues, which can contribute to their antihypertensive response. Currently, new imidazoline receptors ligands are in development. CONCLUSION In the present review, we provide a brief update on the cardiovascular effects of clonidine, moxonidine, rilmenidine, and the novel imidazoline agents since representing an important therapeutic target for some cardiovascular diseases.
Collapse
Affiliation(s)
- Luis Cobos-Puc
- Department of Pharmacology, Faculty of Chemistry, Autonomous University of Coahuila, Saltillo, Mexico
| | - Hilda Aguayo-Morales
- Department of Pharmacology, Faculty of Chemistry, Autonomous University of Coahuila, Saltillo, Mexico
| |
Collapse
|
5
|
Tromp TR, Mahesh D, Joles JA, Ramchandra R. Direct Recording of Cardiac and Renal Sympathetic Nerve Activity Shows Differential Control in Renovascular Hypertension. Hypertension 2018; 71:1108-1116. [PMID: 29686011 DOI: 10.1161/hypertensionaha.117.10749] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Revised: 12/27/2017] [Accepted: 03/21/2018] [Indexed: 02/07/2023]
Abstract
There is increasing evidence that hypertension is initiated and maintained by elevated sympathetic tone. Increased sympathetic drive to the heart is linked to cardiac hypertrophy in hypertension and worsens prognosis. However, cardiac sympathetic nerve activity (SNA) has not previously been directly recorded in hypertension. We hypothesized that directly recorded cardiac SNA levels would be elevated during hypertension and that baroreflex control of cardiac SNA would be impaired during hypertension. Adult ewes either underwent unilateral renal artery clipping (n=12) or sham surgery (n=15). Two weeks later, electrodes were placed in the contralateral renal and cardiac nerves to record SNA. Baseline levels of SNA and baroreflex control of heart rate and sympathetic drive were examined. Unilateral renal artery clipping induced hypertension (mean arterial pressure 109±2 versus 91±3 mm Hg in shams; P<0.001). The heart rate baroreflex curve was shifted rightward but remained intact. In the hypertensive group, cardiac sympathetic burst incidence (bursts/100 beats) was increased (39±14 versus 25±9 in normotensives; P<0.05), whereas renal sympathetic burst incidence was decreased (69±20 versus 93±8 in normotensives; P<0.01). The renal sympathetic baroreflex curve was shifted rightward and showed increased gain, but there was no change in the cardiac sympathetic baroreflex gain. Renovascular hypertension is associated with differential control of cardiac and renal SNA; baseline cardiac SNA is increased, whereas renal SNA is decreased.
Collapse
Affiliation(s)
- Tycho R Tromp
- From the Department of Physiology, The University of Auckland, New Zealand (T.R.T., D.M., R.R.)
| | - Darvina Mahesh
- From the Department of Physiology, The University of Auckland, New Zealand (T.R.T., D.M., R.R.)
| | - Jaap A Joles
- and Department of Nephrology and Hypertension, University Medical Centre Utrecht, The Netherlands (T.R.T., J.A.J.)
| | - Rohit Ramchandra
- From the Department of Physiology, The University of Auckland, New Zealand (T.R.T., D.M., R.R.);
| |
Collapse
|
6
|
Role of renal nerves in the treatment of renovascular hypertensive rats with L-arginine. Int J Hypertens 2014; 2014:735627. [PMID: 25349722 PMCID: PMC4199080 DOI: 10.1155/2014/735627] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2014] [Revised: 08/24/2014] [Accepted: 09/09/2014] [Indexed: 12/19/2022] Open
Abstract
The purpose was to determine the role of renal nerves in mediating the effects of antihypertensive treatment with L-arginine in a renovascular hypertension model. The 2K1C (two-kidney one-clip model) hypertensive rats were submitted to bilateral surgical-pharmacological renal denervation. The animals were subdivided into six experimental groups: normotensive control rats (SHAM), 2K1C rats, 2K1C rats treated with L-arginine (2K1C + L-arg), denervated normotensive (DN) rats, denervated 2K1C (2K1C + DN) rats, and denervated 2K1C + L-arg (2K1C + DN + L-arg) rats. Arterial blood pressure, water intake, urine volume, and sodium excretion were measured. The 2K1C rats exhibited an increase in the mean arterial pressure (MAP) (from 106 ± 3 to 183 ± 5.8 mmHg, P < 0.01), whereas L-arg treatment induced a reduction in the MAP (143 ± 3.4 mmHg) without lowering it to the control level. Renal nerve denervation reduced the MAP to normotensive levels in 2K1C rats with or without chronic L-arg treatment. L-arg and denervation induced increases in water intake and urine volume, and L-arg caused a significant natriuretic effect. Our results suggest that renal sympathetic activity participates in the genesis and the maintenance of the hypertension and also demonstrate that treatment with L-arg alone is incapable of normalizing the MAP and that the effect of such treatment is not additive with the effect of kidney denervation.
Collapse
|
7
|
Gomes AC, Falcão-Pires I, Pires AL, Brás-Silva C, Leite-Moreira AF. Rodent models of heart failure: an updated review. Heart Fail Rev 2013; 18:219-49. [PMID: 22446984 DOI: 10.1007/s10741-012-9305-3] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Heart failure (HF) is one of the major health and economic burdens worldwide, and its prevalence is continuously increasing. The study of HF requires reliable animal models to study the chronic changes and pharmacologic interventions in myocardial structure and function and to follow its progression toward HF. Indeed, during the past 40 years, basic and translational scientists have used small animal models to understand the pathophysiology of HF and find more efficient ways of preventing and managing patients suffering from congestive HF (CHF). Each species and each animal model has advantages and disadvantages, and the choice of one model over another should take them into account for a good experimental design. The aim of this review is to describe and highlight the advantages and drawbacks of some commonly used HF rodents models, including both non-genetically and genetically engineered models, with a specific subchapter concerning diastolic HF models.
Collapse
Affiliation(s)
- A C Gomes
- Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319, Porto, Portugal
| | | | | | | | | |
Collapse
|
8
|
Renal sympathetic activation from long-term low-dose angiotensin II infusion in rabbits. J Hypertens 2012; 30:551-60. [DOI: 10.1097/hjh.0b013e328350133a] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|